Dianthus TherapeuticsDNTH
Recorded

Dianthus Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration33 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Ash VermaSMID-cap Biotech and Spec Pharma

Good day, everybody. My name is Ash Verma. I cover SMID-cap biotech and spec pharma at UBS, and really excited to have Dianthus, Marino Garcia, who is the CEO. Thank you so much for joining us. Very excited to learn more about Dianthus today, and I know you have some slides that you want to run through, and then we can get into some Q&A.

Marino GarciaCEO

Thank you, Ash, and thank you to UBS for this opportunity to update everyone on all the exciting developments at Dianthus Therapeutics. I will just take a few moments to set the stage, and then we can jump into the questions. Just obviously, I will be making some forward-looking statements, so I just refer everyone to our website and our SEC filings for all the appropriate risks around Dianthus and investing in the company. Before I jump into our lead program and set the stage for claseprubart, Dianthus, what we are trying to do is build a very exciting autoimmune-focused biotech company. We have three programs. Our lead program, claseprubart, is a highly potent extended half-life active C1s inhibitor that inhibits only the classical pathway, leaving the lectin alternative pathways intact. We will talk a little bit about what that means in terms of its differentiation. Our second program is DNTH212.

Marino GarciaCEO

It is a bifunctional fusion protein that we in-licensed from China last year. On one side, it is a BDCA2 inhibitor that has demonstrated superior pDC depletion when compared to litifilimab, which is in Biogen's portfolio, and we will be reading out two phase III SLE studies in the first half of December. On the other side, it targets BAFF/APRIL for pDC modulation, and there it looks very similar in terms of Ig reductions to povetacicept, which is the best in class BAFF/APRIL, but with an extended half-life compared to povetacicept. There again, what we are targeting is in phase I, and what we are targeting is to go into conditions like SLE, dermatomyositis, and Sjögren's, with the idea of bringing the two mechanisms together to bring about potentially superior efficacy to any one monotherapy approach.

Marino GarciaCEO

Finally, DNTH312, which came out of our small but mighty research team, that is on one side claseprubart, a very potent, again, extended half-life active C1s inhibitor, and on the other BAFF/APRIL. Again, there it looks in NHPs, looks similar in terms of Ig reduction as povetacicept again, but with an extended half-life as well. There again, we are looking to take it into conditions like MG, CIDP, and MMN, like our first program, as well as other indications, and it is there to be that next-generation antibody that could potentially bring about better efficacy, maybe help treat more patients, more symptoms across various indications compared to any one approach, whether active C1s inhibition or BAFF/APRIL. Back to our first program, which will obviously be a big part of our focus, claseprubart. What are we trying to achieve?

Marino GarciaCEO

What we are trying to achieve here are three elements. One is best in disease efficacy. We are targeting rapid, sustained, consistent efficacy, and I will talk a little bit about that in a moment. More differentiated safety, certainly versus any other complement inhibitor. Because we inhibit only the classical pathway, we leave the lectin alternative pathways intact, and those are the pathways you need to be able to fight against the risk of serious infections from encapsulated bacteria. So we are, for example, in the myasthenia gravis market, we are looking to be the absolute only complement inhibitor with no boxed warning, no REMS program. Finally, patient-friendly convenience. We are targeting either every two weeks in CIDP and MMN, or every four weeks in myasthenia gravis with an auto-injector, the exact same auto-injector as DUPIXENT.

Marino GarciaCEO

If you want to see how easy it is, just go to the DUPIXENT website, and you can watch the patient video there. It would be self-administered in about five seconds. I mentioned we are looking for about superior efficacy. What gives us the confidence to be able to say something like that? On the left side of this slide, unlike C5 inhibitors, the one thing by being an upstream inhibitor, by inhibiting active C1s in the classical pathway only, what we are able to do that C5s cannot is prevent things like the formation of C3a and the deposition of C3b. C5s act too late to prevent these pro-inflammatory toxic split products. We inhibit the classical pathway and stop the complement cascade earlier. These are causing continuous inflammation and damage at the neuromuscular junction for myasthenia gravis patients.

Marino GarciaCEO

So we believe this will bring about a higher MG-ADL, and potentially better efficacy numbers than C5 inhibitors in MG. This mechanism is why we work in CIDP and MMN, and you do not see C5s in CIDP and MMN. They just act too late to prevent this part of the complement cascade. So in the middle, and on the right, you see the two complement inhibitors that are being studied in CIDP and MMN. In the middle, you see our potency relative difference to riliprubart, where we look like at the IC90 using the CH50 hemolytic assay, we are about seven times more potent. It is being studied in CIDP. They have one failed phase III study in refractory patients. They have another one ongoing in stable on standard of care therapy patients.

Marino GarciaCEO

Finally, on the right, you can see our difference in potency versus empasiprubart, the C2 inhibitor in argenx's portfolio, which will read out MMN phase III data in December and CIDP data, I believe, by the end of next year. Again, you can see the relative potency differences between our claseprubart and those two complement inhibitors is pretty dramatic. I mentioned that argenx will have phase III data in MMN in December. We will have our proof of concept phase II results also in December in MMN. It is a very small study with a primary endpoint of being safety, but of course, we have grip strength and other muscle strength measures as secondary endpoints. We were targeting 12 patients per arm in placebo, 300 milligrams every two weeks, and 600 milligrams every two weeks.

Marino GarciaCEO

We over-enrolled, which is great, so we'll have about 15 patients per arm. As I mentioned, this will be reading out in December. Of course, people will want to see how we compare to the phase II data from empasiprubart and C2, so I want to caution that there is one major difference between our two programs, and that's in the protocol of deciding which patients get IVIG rescue. in our protocol, you would say it makes sense, we only gave IVIG rescue to patients who had a documented clinical deterioration. If you did not have clinical deterioration documented, you did not get IVIG rescue.

Marino GarciaCEO

But, interestingly, in the phase II ARDA trial from empasiprubart, where they made a lot of noise around their 91% reduction in the need for IVIG rescue for empasiprubart compared to placebo, interestingly, they had patients who had clinical deterioration on empasiprubart that did not get IVIG rescue. They had patients on placebo that had no clinical deterioration and did get IVIG rescue. It's a little bit odd. Not sure why they did it that way. We certainly didn't do it that way. So, what I want to make sure that investors keep in mind is, it's absolutely fair to compare on safety, it's absolutely fair to compare on grip strength, and what our numerical trends look like versus, excuse me, empasiprubart, but you can't look at IVIG rescue. What I would suggest is look at relapse rates.

Marino GarciaCEO

I think for that cohort where they saw the 91% reduction in IVIG rescue, they said, if you look at just relapse rates differences between empasiprubart and the placebo, the number is actually 58% reduction and not statistically significant. So, I would look at grip strength as a secondary endpoint, relapse rates, those are probably fair to compare across the two. Finally, differentiation between claseprubart and empasiprubart. As I mentioned, we are much more potent in terms of inhibiting the classical pathway. We'll see if that matters in MMN. It looks like potency differences versus riliprubart do matter in CIDP. We don't have the evidence yet to say definitively whether potency will matter in MMN or not. We leave the lectin pathway intact. Empasiprubart inhibits the lectin pathway. That's the pathway that you need to initiate the complement cascade when it detects encapsulated bacteria.

Marino GarciaCEO

The lectin pathway is initiated, that revs up the alternate pathway, that forms MAC, which then destroys or lyses the encapsulated bacteria. They inhibit it, therefore they're likely to get a boxed warning for the risk of infections, like C5s, like every terminal inhibitor. We won't. We have the precedent of ENJAYMO, sutimlimab, which is approved in the U.S. for cold agglutinin disease and has no boxed warning in REMS program. Finally, they're an IV every four weeks. We will be an auto-injector, self-administered, just like the DUPIXENT auto-injector, the SHL model it's called, every two weeks. So, we'll definitely be a more convenient option. With that, let's go to Q&A.

Ash VermaSMID-cap Biotech and Spec Pharma

Great. Awesome. Yeah, thank you so much. Maybe just like a high-level overview question. I guess, a few different indications that you are pursuing, right? Myasthenia gravis, CIDP, and MMN. The way that you think of it, obviously, some of these indications have more competition than the others, like MMN, definitely a lot of white space there. When you think about the addressable market opportunity for your platform, is MMN a big part of it?

Ash VermaSMID-cap Biotech and Spec Pharma

Yeah. Or where do you see sort of the segmentation of the revenue opportunity for you?

Marino GarciaCEO

Sure. Well, when we went public, at that point, I would say to investors, MG is our biggest commercial opportunity, then CIDP, then MMN.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day